Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab

Australas J Dermatol. 2018 May;59(2):131-134. doi: 10.1111/ajd.12744. Epub 2017 Dec 4.

Abstract

An increased expression of interleukin-23 has been observed in patients with pyoderma gangrenosum, leading to the use of ustekinumab as a therapeutic option. We report the successful use of ustekinumab in three patients with treatment-resistant pyoderma gangrenosum of varying clinical presentations.

Keywords: pyoderma gangrenosum; treatment; ustekinumab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Infective Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Chronic Disease
  • Dermatologic Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Middle Aged
  • Pyoderma Gangrenosum / drug therapy*
  • Retreatment
  • Ustekinumab / therapeutic use*

Substances

  • Anti-Infective Agents
  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Immunologic Factors
  • Ustekinumab